Endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, affects approximately one in ten women of reproductive age, leading to chronic pain, heavy periods, and fertility challenges. Managing this complex condition often requires a multifaceted approach, including medications, hormonal therapies, and sometimes surgery.
In a recent Instagram reel, Dr Anjali Kumar, known as Maitri Woman, discussed Elagolix in detail, which is a medication designed to alleviate endometriosis-associated pain by lowering estrogen levels. She highlighted that while Elagolix can provide rapid pain relief within months, it is not a cure and may come with side effects such as hot flashes, bone loss, and mood changes. Here is everything you need to know!
Understanding Elagolix
Elagolix, marketed under the brand name Orilissa, is an oral gonadotropin-releasing hormone (GnRH) antagonist. It works by suppressing ovarian hormone production, leading to decreased estrogen levels, which can reduce endometriosis-related pain. Clinical studies have demonstrated that Elagolix effectively reduces moderate-to-severe endometriosis pain, including dysmenorrhea (painful periods) and non-menstrual pelvic pain.
Also Read: Walking 1km vs Running 1km: Which One Should You Choose
Potential Side Effects
According to Dr Kumar, while Elagolix offers a non-surgical option for pain management, it is associated with several side effects:
Hot Flashes and Night Sweats: Commonly reported by users, these symptoms result from decreased estrogen levels.
Bone Density Reduction: Long-term use can lead to decreased bone mineral density, increasing the risk of osteoporosis.
Mood Changes: Some individuals may experience mood swings, depression, or anxiety. In rare cases, suicidal thoughts have been reported, necessitating close monitoring, especially for those with a history of mental health issues.
Components of Comprehensive Care
It's crucial to recognise that while Elagolix can significantly reduce pain, it does not cure endometriosis. Effective management often requires a combination of treatments tailored to the individual's symptoms and reproductive goals. Options may include hormonal contraceptives, pain relievers, lifestyle modifications, and, in some cases, surgical interventions.
Also Read: Walking 1km vs Running 1km: Which One Should You Choose
Recent Developments in Endometriosis Treatment
In March 2025, the National Institute for Health and Care Excellence (NICE) approved a new daily pill, relugolix-estradiol-norethisterone (Ryeqo), for use in the NHS in England. This medication offers a novel approach by combining hormone-blocking properties with hormone replacement, aiming to provide effective pain relief with potentially fewer side effects. Approximately 1,000 women annually are expected to benefit from this treatment.
Personal Experiences and Considerations
Individual responses to endometriosis treatments can vary. Some patients have reported significant relief with medications like Elagolix, while others have encountered challenges due to side effects. For instance, one patient shared her experience with relugolix combination therapy, noting severe mood changes that led her to discontinue the medication.
Bottomline
Elagolix represents a valuable tool in the management of endometriosis-associated pain, offering rapid relief for many. However, it's essential to weigh the benefits against potential side effects and to consider it as part of a broader, individualized treatment strategy. Consulting with a healthcare provider experienced in endometriosis care is crucial to determine the most appropriate approach for each patient.